Cleveland BioLabs (NASDAQ:CBLI) Stock Quotes and News | Benzinga

Benzinga - Feed Your Mind.

Market Overview

3.130 0.027 (0.85%)

Data as of Oct 23, 2017

Prev. Close 3.1035
Price Open 3.1466
Volume 4,838
Day's Range 3.1093 - 3.25
52 Wk Range 1.22 - 5.55
50 Day Moving Avg. 2.928156
PE Ratio 0
Shares Outstanding 10.99M
Market Cap 34.39M

Analyst Rating View All Ratings

Cleveland Biolabs Reports Q2 EPS $(0.50) vs $(0.17) In Same Qtr. Last Year, Grants And Contract Sales ~$206K Paul QuintaroMon, 14 Aug 2017 08:23:24 -0400
Cleveland Biolabs Up ~10% Off The Open As Traders Are Passing Around Speculative Chatter Of Dept. Of Possible Defense Nuclear Contract Paul QuintaroWed, 09 Aug 2017 09:57:55 -0400
8-K from Cleveland Biolabs Shows Co.'s Principal Financial Officer, John Szydlo, Will Resign; Co.'s CEO Will Serve as Interim Principal Financial Officer Paul QuintaroFri, 02 Jun 2017 16:44:29 -0400
22 Stocks Moving In Friday's Pre-Market Session Lisa LevinFri, 19 May 2017 08:11:23 -0400
Clevaeland BioLabs Q1 EPS $(0.06), Sales $575K Paul QuintaroMon, 15 May 2017 07:32:01 -0400
Volume Spike in Cleveland Biolabs Charles GrossFri, 12 May 2017 10:55:21 -0400
Traders Attributing Recent ~$0.10/Share Move Higher in Cleveland BioLabs to Report No Radiation Was Detected Following Tunnel Collapse at Hanford Nuclear Site Paul QuintaroTue, 09 May 2017 13:06:32 -0400
UPDATE: Cleveland BioLabs CFO C. Neil Lyons Steps Down Charles GrossWed, 26 Apr 2017 16:26:48 -0400
Cleveland BioLabs Names John Szydlo as Principal Financial Officer -8-K Charles GrossWed, 26 Apr 2017 16:24:38 -0400
Cleveland Biolabs Pops to High of $4.05 on Volume Charles GrossMon, 24 Apr 2017 10:02:37 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Cleveland BioLabs Reports Second Quarter 2017 Financial Results and Development Progress MarketwiredAug 14, 2017
Cleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress MarketwiredMay 15, 2017
Governments Looking at Cleveland Biolabs Radiation Countermeasure PRLiveApr 20, 2017
Cleveland BioLabs Announces Webcast of Annual Meeting MarketwiredApr 11, 2017
Cleveland BioLabs Reports 2016 Financial Results and Development Progress MarketwiredFeb 22, 2017
Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014 Business WireAug 11, 2014
Cleveland BioLabs to Present at 2014 BIO CEO & Investor Conference Globe NewswireFeb 04, 2014
Glancy Binkow & Goldberg LLP Announces Investigation of Cleveland BioLabs, Inc. Business WireJan 24, 2014
Investor Alert: Cleveland BioLabs, Inc. Investigation Announced by Holzer & Holzer, LLC Business WireJan 24, 2014
Cleveland BioLabs Provides Update on Barda Development Proposal Globe NewswireJan 23, 2014
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Cleveland BioLabs reports Q4 results Seeking AlphaFeb 22, 2017
Cleveland BioLabs reports Q3 results Seeking AlphaNov 14, 2016
Accelerated Pharma IPO Has A Tiny Chance Among Big Players Seeking AlphaNov 08, 2016
Midday Gainers / Losers Seeking AlphaSep 06, 2016
Healthcare - Top 5 Gainers / Losers as of 11:00 am Seeking AlphaSep 06, 2016
Cleveland BioLabs reports Q2 results Seeking AlphaAug 15, 2016
Cleveland BioLabs Announces Webcast of Annual Meeting GuruFocusApr 05, 2016
Cleveland BioLabs Provides Update on Pre-EUA Review of Entolimod as Radiation Countermeasure GuruFocusMar 17, 2016
Cleveland BioLabs reports Q4 results Seeking AlphaFeb 22, 2016
Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T ... GuruFocusFeb 10, 2016
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q2 2017	EST	Actual	Surprise
EPS:	Expected 2017-08-14
Rev:	Expected 2017-08-14

Q3 2017	EST	Actual	Surprise
EPS:	Expected 2017-11-13
Rev:	Expected 2017-11-13